These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11782030)

  • 1. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections.
    Schäfer H; Müller HH
    Stat Med; 2001 Dec; 20(24):3741-51. PubMed ID: 11782030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections, by H. Schäfer and H.-H. Müller, Statistics in Medicine 2001; 20: 3741-3751.
    Bauer P; Posch M
    Stat Med; 2004 Apr; 23(8):1333-4; author reply 1334-5. PubMed ID: 15083486
    [No Abstract]   [Full Text] [Related]  

  • 3. A general statistical principle for changing a design any time during the course of a trial.
    Müller HH; Schäfer H
    Stat Med; 2004 Aug; 23(16):2497-508. PubMed ID: 15287080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non small-cell lung cancer.
    Leo F; De Pas T; Catalano G; Piperno G; Curigliano G; Solli P; Veronesi G; Petrella F; Spaggiari L
    J Natl Cancer Inst; 2007 Aug; 99(15):1210; author reply 1210-1. PubMed ID: 17652281
    [No Abstract]   [Full Text] [Related]  

  • 5. Seamlessly expanding a randomized phase II trial to phase III.
    Inoue LY; Thall PF; Berry DA
    Biometrics; 2002 Dec; 58(4):823-31. PubMed ID: 12495136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Karrison TG; Maitland ML; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triangular test and randomized trials: practical problems in a small cell lung cancer trial.
    Pignon JP; Tarayre M; Auquier A; Arriagada R; Le Chevalier T; Ruffié P; Rivière A; Monnet I; Chomy P; Tuchais C
    Stat Med; 1994 Jul 15-30; 13(13-14):1415-21. PubMed ID: 7973221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What should the optimal timing be for amifostine administration relative to radiation and chemotherapy?
    Komaki R
    J Clin Oncol; 2005 Oct; 23(28):7232-3; author reply 7233-5. PubMed ID: 16192612
    [No Abstract]   [Full Text] [Related]  

  • 9. Surgery in stage III non-small-cell lung cancer.
    Eberhardt WE; Stamatis G; Stuschke M
    Lancet; 2009 Aug; 374(9687):359-60. PubMed ID: 19632715
    [No Abstract]   [Full Text] [Related]  

  • 10. A useful design utilizing the information fraction in a group sequential clinical trial with censored survival data.
    Hsu CY; Chen CH; Hsu KN; Lu YH
    Biometrics; 2019 Mar; 75(1):133-143. PubMed ID: 30004574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size adjustment designs with time-to-event outcomes: A caution.
    Freidlin B; Korn EL
    Clin Trials; 2017 Dec; 14(6):597-604. PubMed ID: 28795844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of accrual and follow-up for two-stage clinical trials.
    Case LD; Morgan TM
    Lifetime Data Anal; 2001 Mar; 7(1):21-37. PubMed ID: 11280845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of clinical studies: adaptive randomization and progression-free survival (PFS) as an endpoint in clinical studies of advanced non-small cell lung cancer (NSCLC).
    Schrimpf D; Manegold C; Pilz LR
    Int J Clin Pharmacol Ther; 2013 Jan; 51(1):84-6. PubMed ID: 23260009
    [No Abstract]   [Full Text] [Related]  

  • 14. Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes!
    Sequist LV; Lynch TJ
    J Clin Oncol; 2003 Sep; 21(17):3186-8. PubMed ID: 12874267
    [No Abstract]   [Full Text] [Related]  

  • 15. Sample size re-estimation for survival data in clinical trials with an adaptive design.
    Togo K; Iwasaki M
    Pharm Stat; 2011; 10(4):325-31. PubMed ID: 22328325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A post hoc evaluation of a sample size re-estimation in the Secondary Prevention of Small Subcortical Strokes study.
    McClure LA; Szychowski JM; Benavente O; Hart RG; Coffey CS
    Clin Trials; 2016 Oct; 13(5):537-44. PubMed ID: 27094488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
    Rossi A; Chiodini P; Sun JM; O'Brien ME; von Plessen C; Barata F; Park K; Popat S; Bergman B; Parente B; Gallo C; Gridelli C; Perrone F; Di Maio M
    Lancet Oncol; 2014 Oct; 15(11):1254-62. PubMed ID: 25232001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K; Porcher R
    Stat Med; 2007 Nov; 26(27):5002-13. PubMed ID: 17577242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A sequential phase II/III trial for binary outcomes.
    Storer BE
    Stat Med; 1990 Mar; 9(3):229-35. PubMed ID: 2160719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.
    BMJ; 1995 Oct; 311(7010):899-909. PubMed ID: 7580546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.